Foods classified as novel generally require pre-market authorization under Regulation (EU) 2015/2283. Eligible traditional foods from third countries may follow a separate notification procedure. The framework generally applies to foods that were not consumed to a significant degree in the European Union before 15 May 1997 and fall within the categories specified by the Regulation.
Applications are submitted to the European Commission and generally undergo a scientific safety assessment by the European Food Safety Authority (EFSA). Applicants must demonstrate that the novel food is safe under its proposed conditions of use through evidence addressing ingredient identity, manufacturing, composition, specifications, dietary exposure, toxicology, nutritional considerations, and allergenicity.
EFSA’s scientific assessment is generally subject to a nine-month timeframe following receipt of a valid application. However, additional information requests may suspend this period, and the subsequent authorization process requires further regulatory consideration. Manufacturers should typically plan for an overall process of approximately 1.5–3 years, potentially longer where additional scientific studies are necessary.
Successful authorization depends on establishing the appropriate regulatory pathway, identifying scientific evidence gaps before submission, and preparing a dossier that adequately supports the safety of the commercial ingredient.
EU Novel Food authorization is the regulatory process through which qualifying foods and food ingredients are evaluated for safety before being permitted on the European Union market.
The framework is established under Regulation (EU) 2015/2283, which defines novel foods as those not consumed to a significant degree within the EU before 15 May 1997 and falling within specified regulatory categories.
The categories include foods with a new or intentionally modified molecular structure; foods consisting of, isolated from, or produced from microorganisms, fungi, algae, or material of mineral origin; certain foods from plants or animals; foods from cell or tissue cultures; and foods produced through processes that cause specified significant changes in composition or structure. They also include foods consisting of engineered nanomaterials, certain vitamins or minerals produced through qualifying new processes or containing engineered nanomaterials, and foods used only in food supplements in the EU before 15 May 1997 when intended for use in other foods. Specific exceptions apply, including for certain plants and animals with a history of safe food use.For example, a manufacturer developing a fermentation-derived protein may need to establish whether the ingredient, production organism, and manufacturing process meet the criteria for novelty. Even when the source organism has an established history of food use, the resulting ingredient may have characteristics that require a separate regulatory assessment.
Unlike the U.S. Generally Recognized as Safe (GRAS) framework, EU Novel Food authorization is a formal pre-market approval process. A U.S. GRAS conclusion does not independently establish permission to market an ingredient in the European Union.
For further information on this distinction, see dicentra’s article, Can a U.S. GRAS Ingredient Be Sold in the European Union?.
Determining whether an ingredient requires authorization is the first step in developing an EU regulatory strategy. Classification depends on the ingredient’s identity, history of consumption, manufacturing process, composition, and intended use.
Several categories are particularly relevant to ingredient manufacturers.
Foods without a significant history of EU consumption: Ingredients traditionally consumed outside Europe may be considered novel when sufficient evidence of consumption within the EU before 15 May 1997 is unavailable. Historical consumption of an unprocessed botanical, for example, does not necessarily establish the regulatory status of a concentrated extract produced using modern extraction methods.
Foods derived from microorganisms, fungi, algae, and other biological sources: These may include certain microbial biomass ingredients, specialized botanical isolates, algae-derived compounds, and fermentation products. Classification should consider the specific commercial material rather than relying exclusively on the history of the source organism.
Foods produced through novel manufacturing processes: A food may qualify as novel where a process not used for food production in the EU before 15 May 1997 causes significant changes in composition or structure affecting nutritional value, metabolism, or undesirable substances. The introduction of a new manufacturing technology does not automatically make a food novel; the resulting changes must meet the regulatory criteria.
Foods derived from cell or tissue cultures: These ingredients may require assessment of the source material, culture conditions, processing aids, residual substances, and final composition.
Traditional foods from third countries: Certain foods with a documented history of safe consumption outside the EU may qualify for a separate notification procedure. Eligibility generally requires evidence of continuous consumption as part of the customary diet of a significant number of people for at least 25 years. Where duly reasoned safety objections arise, an authorization application may become necessary.
Manufacturers should first consult the European Commission’s Novel Food Catalogue and the Union List of authorized novel foods.
The Novel Food Catalogue provides non-binding guidance and is not exhaustive. An ingredient’s absence from the Catalogue does not establish that it is non-novel.
The Union List identifies authorized novel foods and their permitted conditions of use, including applicable specifications, food categories, maximum use levels, and labeling requirements. Manufacturers should determine whether an existing authorization covers their proposed ingredient and whether any data-protection restrictions apply.
Where classification remains uncertain, Regulation (EU) 2015/2283 provides a consultation procedure involving the competent authority of the Member State where the food business operator first intends to market the product.
Importantly, an ingredient considered non-novel may still be subject to other EU food legislation. Similarly, an ingredient historically used only in food supplements may require a separate novelty assessment when proposed for use in conventional foods.
EU Novel Food applications must contain sufficient scientific evidence for EFSA to determine whether the ingredient is safe under its proposed conditions of use.
The primary reference is EFSA’s 2024 Guidance on the Scientific Requirements for an Application for Authorisation of a Novel Food.
The guidance identifies minimum information requirements concerning identity, production, composition, specifications, proposed uses, use levels, and anticipated intake. Additional sections address history of use, absorption and metabolism, toxicology, nutrition, and allergenicity.
Not every ingredient requires the same scientific studies. However, applicants must provide a scientific justification where particular evidence or additional testing is considered unnecessary.
Ingredient Identity and Manufacturing
The dossier must establish precisely what material is being evaluated and how it is produced.
Depending on the ingredient, identity information may include chemical characterization, taxonomic identification, source organism details, molecular structure, and relevant physical or chemical properties.
Manufacturing documentation should describe raw materials, processing methods, purification steps, quality controls, and potential contaminants or residues.
For example, a fermentation-derived ingredient may require strain-level identification of the production organism, information about fermentation conditions, downstream processing, and evidence demonstrating that the finished ingredient is consistently manufactured.
These details are essential because EFSA’s safety assessment applies to the characterized material. Differences between the tested ingredient and the commercial product may affect the applicability of supporting scientific evidence.
Compositional Data and Specifications
Applicants must demonstrate that the novel food can be adequately characterized and manufactured consistently.
Relevant evidence may include representative batch analyses, nutrient composition, characteristic constituents, impurity profiles, microbiological parameters, and other specifications appropriate to the ingredient.
Analytical methods should be suitable for their intended purpose, and specifications should reflect the material evaluated in the safety studies.
For example, toxicological studies conducted on a purified ingredient may not adequately support a commercial product containing materially different impurities unless those differences are scientifically justified.
Proposed Uses and Dietary Exposure
EFSA evaluates ingredient safety in relation to the proposed food categories, use levels, target populations, and anticipated dietary exposure.
Applicants must estimate how much of the novel food consumers may ingest under the proposed conditions of use, including cumulative exposure from multiple food categories where relevant.
For example, an ingredient intended for beverages, snack foods, and food supplements may require an assessment of combined exposure across those applications.
Where appropriate, the assessment should consider population groups with higher consumption levels or particular susceptibility.
Toxicological Evidence and Metabolism
The extent of toxicological evidence required depends on the ingredient’s characteristics, anticipated exposure, available scientific literature, and potential safety concerns.
Relevant information may include genotoxicity, repeated-dose toxicity, reproductive or developmental toxicity, human safety data, and absorption, distribution, metabolism, and excretion (ADME).
EFSA’s 2024 guidance emphasizes a tiered approach that considers existing evidence before determining whether additional studies are necessary.
For example, a well-characterized ingredient supported by relevant published toxicological studies may not require an entirely new testing program. Conversely, a newly developed microbial ingredient with limited safety information may require additional studies.
Where new studies are necessary, manufacturers should consider applicable OECD test guidelines, Good Laboratory Practice requirements, and EFSA’s study notification obligations.
Nutritional Assessment, Allergenicity, and History of Use
Novel foods must not present unacceptable nutritional disadvantages or allergenic risks.
Nutritional assessments may examine nutrient composition, bioavailability, antinutritional factors, and the consequences of replacing conventional foods.
Allergenicity assessments may consider the ingredient’s biological source, protein characteristics, known allergens, and effects of processing.
Historical consumption information may also support a safety assessment, provided the previously consumed material is sufficiently comparable to the proposed commercial ingredient.
For example, traditional consumption of a botanical in small quantities may not establish the safety of a concentrated extract intended for substantially higher daily exposure.
Applicants must critically evaluate the available evidence, address uncertainties, and explain how the complete scientific package supports safety under the proposed conditions of use.
The standard authorization process involves regulatory classification, scientific preparation, submission, EFSA assessment, and a final decision by the European Commission.
Administrative requirements are established under Commission Implementing Regulation (EU) 2017/2469, while EFSA provides additional scientific and procedural guidance.
Step 1: Confirm the Regulatory Pathway
Manufacturers should establish whether the ingredient is novel, whether an existing Union List authorization applies, and whether an alternative procedure is available.
This assessment should consider ingredient identity, consumption history, manufacturing, and intended use.
Where appropriate, a formal novelty consultation may help resolve uncertainty before substantial investment in dossier preparation.
Step 2: Conduct a Scientific Evidence Gap Assessment
Existing scientific information should be evaluated against EFSA’s requirements to identify missing evidence.
This may include reviewing manufacturing documentation, compositional analyses, specifications, toxicological studies, literature, and dietary exposure assessments.
For example, a manufacturer may have extensive toxicological information but insufficient batch data demonstrating that the commercial ingredient is comparable to the material evaluated in those studies.
Identifying these gaps early allows the manufacturer to develop an appropriate testing and documentation strategy before submission.
Step 3: Complete Pre-Submission Requirements
Applicants can use Connect.EFSA to obtain a pre-application identification number, request general pre-submission advice, and complete applicable study notifications.
Under the EU transparency framework, studies commissioned or carried out to support applications after 27 March 2021 are generally subject to notification requirements before they begin.
Manufacturers should incorporate these obligations into their study planning because non-compliance can create procedural complications.
Step 4: Prepare and Submit the Dossier
The applicant compiles the administrative information and scientific evidence into a structured dossier and submits the application through the European Commission’s electronic submission arrangements.
The dossier should identify the novel food, describe its manufacturing process and proposed uses, present the relevant scientific evidence, and explain how that evidence supports safety.
Applicants must also comply with applicable transparency and confidentiality requirements. Non-confidential information may be published during the review process, while eligible confidential information must be identified through the prescribed procedures.
Step 5: Undergo EFSA Scientific Assessment
Following validation and the applicable suitability checks, EFSA evaluates the scientific evidence supporting the application.
The assessment generally involves EFSA’s Panel on Nutrition, Novel Foods and Food Allergens (NDA), which considers the ingredient’s identity, composition, manufacturing, exposure, toxicological profile, and other relevant safety information.
EFSA may request additional information where the evidence is insufficient. Such requests can suspend the assessment clock until the applicant provides the required response.
The scientific review concludes with EFSA’s adoption of an opinion addressing the safety of the novel food under its proposed conditions of use.
Step 6: Receive the Authorization Decision
Following EFSA’s scientific assessment, the European Commission and Member States determine whether the novel food should be authorized.
A favourable EFSA opinion does not itself authorize commercialization.
Where authorization is granted, the novel food is added to the Union List through the applicable implementing act.
The authorization may establish specific conditions concerning product specifications, permitted uses, maximum levels, labeling, and other restrictions.
Manufacturers must comply with these conditions before placing the ingredient on the EU market.
The total authorization timeline depends on the completeness of the dossier, scientific complexity, additional information requests, and regulatory decision-making.
Although EFSA’s scientific assessment is generally subject to a nine-month timeframe, the complete process includes additional administrative and regulatory stages.
EU Novel Food Authorization Timelines
| Review Stage | Timeline | Description |
| Regulatory assessment and dossier preparation | Variable | Novelty determination, evidence review, study planning, and dossier development |
| Initial Commission review | Generally up to 1 month for the relevant validity and referral step | Initial processing and referral for scientific assessment where applicable |
| EFSA scientific assessment | Generally 9 months | Safety evaluation following receipt of a valid application |
| Additional information requests | Variable | Scientific assessment may be suspended while additional evidence is provided |
| Commission authorization procedure | Generally within 7 months after publication of EFSA’s opinion, subject to extensions | The Commission submits a draft implementing act to the Standing Committee. This period is not a guaranteed deadline for final authorization or market entry. |
| Overall project duration | Often approximately 1.5–3 years or longer | Indicative planning range, not a guaranteed approval timeframe |
The statutory review periods should not be interpreted as a guaranteed authorization schedule.
For example, an ingredient supported by complete manufacturing documentation, validated analytical methods, and relevant toxicological evidence may progress more efficiently than a newly developed ingredient requiring substantial additional testing.
Manufacturers should therefore account for scientific development and dossier preparation when establishing commercial launch schedules, rather than planning exclusively around the formal review periods.
Applications may experience delays when the submitted evidence does not adequately support the safety of the proposed commercial ingredient or when procedural requirements remain incomplete.
The following deficiencies can result in additional information requests or prolonged scientific review.
| Potential Deficiency | Regulatory Implication | Recommended Approach |
| Incomplete ingredient characterization | Uncertainty about the material being assessed | Provide appropriate identity and source information |
| Insufficient manufacturing documentation | Potential process-related hazards remain unresolved | Document production methods, controls, and relevant residues |
| Inadequate compositional data | Product consistency cannot be established | Provide representative batch analyses and justified specifications |
| Incomplete dietary exposure assessment | Safety under proposed conditions of use remains uncertain | Assess relevant food categories, use levels, and populations |
| Insufficient toxicological evidence | Additional studies or scientific justification may be requested | Conduct an evidence gap assessment before submission |
| Unresolved allergenicity concerns | Potential safety risks remain insufficiently characterized | Provide an appropriate allergenicity assessment |
| Differences between tested and commercial materials | Existing evidence may not support the proposed ingredient | Establish scientifically justified comparability |
| Incomplete responses to EFSA requests | Review may remain suspended or encounter further complications | Provide comprehensive responses within applicable deadlines |
These deficiencies are not necessarily grounds for rejection, but they may prevent EFSA from reaching a favourable safety conclusion without additional information.
A scientifically structured dossier should explain how each evidence category contributes to the overall safety assessment and address uncertainties rather than simply compiling available studies.
Authorization permits a novel food to be marketed only in accordance with the applicable Union List conditions.
These conditions may specify the authorized ingredient’s identity, composition, food categories, maximum use levels, target populations, and labeling requirements.
For example, an ingredient authorized for food supplements at a specified daily intake cannot automatically be used in beverages or other food categories unless those uses are covered by the authorization.
Changes to manufacturing processes, specifications, or conditions of use may require further regulatory assessment or modification of an existing authorization.
Manufacturers must also consider any applicable proprietary data-protection provisions, which may restrict another operator’s ability to rely on protected scientific evidence during the relevant protection period.
Consequently, obtaining authorization is not the final regulatory consideration. Manufacturers must ensure that commercial products remain consistent with the conditions under which the novel food was authorized.
EU Novel Food authorization requires specialized regulatory and scientific expertise to determine the appropriate pathway, evaluate supporting evidence, and prepare a complete safety assessment dossier.
With more than two decades of regulatory consulting experience, dicentra supports ingredient manufacturers, food companies, and innovators seeking access to the European Union market.
Our regulatory and scientific specialists assist with Novel Food status determinations, regulatory feasibility assessments, evidence gap analyses, ingredient characterization, manufacturing assessments, dietary exposure evaluations, toxicological assessments, and dossier preparation.
Where additional scientific evidence is necessary, dicentra can help develop an appropriate study strategy and coordinate relevant toxicological, stability, or clinical research activities.
Our team also supports applicants throughout regulatory review, including responding to EFSA’s scientific questions and evaluating post-authorization compliance requirements.
Learn more about dicentra’s EU Novel Food Submission Services.
Manufacturers introducing innovative ingredients into the European Union must establish the appropriate regulatory pathway and provide scientific evidence demonstrating safety under the proposed conditions of use.
Early assessment of the available evidence can help identify potential deficiencies, determine whether additional studies are necessary, and reduce avoidable delays during regulatory review.
Contact dicentra’s regulatory experts to discuss your EU Novel Food application, evaluate your supporting scientific evidence, and develop an effective regulatory strategy for European market authorization.
Stay up to date on regulatory and compliance updates, news, and events!
Please complete the form below to register for the summit. All fields are required.